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Abstract
Background: H5N1 is a highly pathogenic influenza A virus, which can cause severe illness or even death in humans.
Although the widely used killed vaccines are able to provide some protection against infection via neutralizing antibodies,
cytotoxic T-lymphocyte responses that are thought to eradicate viral infections are lacking.
Methodology/Principal Findings: Aiming to promote cytotoxic responses against H5N1 infection, we extended our
previous finding that praziquantel (PZQ) can act as an adjuvant to induce IL-17-producing CD8
+ T cells (Tc17). We found that
a single immunization of 57BL/6 mice with killed viral vaccine plus PZQ induced antigen-specific Tc17 cells, some of which
also secreted IFN-c. The induced Tc17 had cytolytic activities. Induction of these cells was impaired in CD8 knockout (KO) or
IFN-c KO mice, and was even lower in IL-17 KO mice. Importantly, the inoculation of killed vaccine with PZQ significantly
reduced virus loads in the lung tissues and prolonged survival. Protection against H5N1 virus infection was obtained by
adoptively transferring PZQ-primed wild type CD8
+ T cells and this was more effective than transfer of activated IFN-c KO or
IL-17 KO CD8
+ T cells.
Conclusions/Significance: Our results demonstrated that adding PZQ to killed H5N1 vaccine could promote broad Tc17-
mediated cytotoxic T lymphocyte activity, resulting in improved control of highly pathogenic avian influenza virus infection.
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Introduction
Avian A/H5N1 Influenza A virus, emerged as a cause of human
disease in recent years that is associated with high mortality and it
poses a major pandemic threat [1–3]. Vaccination has its
advantages over other approaches for limiting potential pandemic
influenza outbreaks. Although, the widely used killed H5N1
vaccine is helpful by eliciting a neutralizing antibody response in
chickens [4], protection against H5N1 infection in humans is likely
to require eliciting both humoral and cellular virus-specific
responses. Eliciting cytolytic T lymphocyte responses may be
particularly important since this has been demonstrated to
eradicate viral infections [5–8]. The induction of broad cytotoxic
T lymphocyte responses to killed H5N1 vaccine is an urgent and
challenging issue.
Adjuvant could be added into the killed vaccine to elicit a robust
and broad cellular immune response [9,10]. Till now, alum and
MF59 are the only two adjuvants approved by the U.S. Food and
Drug Administration (FDA) for use in influenza vaccines [9,11],
but both are limited by minimal induction of cell-mediated
immunity [12–16]. Novel adjuvants are therefore needed to
enhance cellular immunity for these killed viral vaccines.
Praziquantel (PZQ) has an excellent record of safety in treating
Schistosomiasis infections [17], and recently we demonstrated that
PZQ could enhance cellular responses to HBsAg DNA vaccination
[18,19]. Therefore we investigate here whether PZQ could
enhance cellular immune responses to the killed H5N1 vaccina-
tion.
In this study, we demonstrated that by using PZQ with a killed
H5N1 vaccine mice could be better protected against a lethal-dose
challenge with H5N1 virus. This protection was strongly
associated with elicitation of more IL-17-producing cytotoxic
CD8
+ T cells (Tc17) when PZQ was used with the killed H5N1
vaccination. This is the first report to show that PZQ has great
potential as an adjuvant to induce strong CD8
+ T cell-immunity
with killed H5N1 vaccine.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34865Results
PZQ as adjuvant induced a high level of cytolytic
response
Since virus specific cytotoxic T lymphocyte activity is indis-
pensable for controlling viral infections [7,8], we first examined
whether adding PZQ to the killed H5N1 vaccine (0.5 mg PZQ/
0.1 mg antigen) could induce higher levels of nucleoprotein (NP)-
specific cytolytic responses. Mice were immunized a single time
and in vivo cytotoxic activity was assayed 7 days later. Compared
to the groups that were immunized with the killed vaccine alone or
the killed vaccine with vehicle, the highest level of antigen-specific
lysis was observed in the mice immunized with the killed vaccine
plus PZQ (Figure 1A–B).
Since antibody production is also an important arm of immune
response, we also tested antibody titers of serum samples taken 14
days after the vaccination. There were no differences between the
groups (Figure 1C), suggesting that PZQ did not affect the
humoral response.
PZQ promoted Tc17 cell activation
Because both IFN-c-producing CD8
+ T cells (Tc1) and IL-17-
producing CD8
+ T cells (Tc17) could contribute to the cytolytic
response [20–22], we sought to determine which subset of T cells
were the main effectors. Splenocytes were isolated 7 days after
immunization and stimulated with NP peptide (ASNENMETM)
in vitro before they were stained for intracellular IFN-c, IL-17 or
both and assayed by flow cytometry. As shown in Figure 2A–B, the
expression of antigen-induced IL-17, but not IFN-c in CD8
+ T
cells was significantly higher in the mice immunized with killed
vaccine plus PZQ compared to other groups. This was confirmed
by the result of double staining shown in Fig. 2.C–D, which
Figure 1. In vivo cytotoxic responses and antibody responses in immunized mice. C57BL/6 mice were immunized with 0.1 mg killed H5N1
vaccine in 100 ul of delivery vehicle, with vehicle alone, with vehicle containing PZQ (0.5 mg PZQ/0.1 mg antigen) or with vaccine in vehicle containing
PZQ. (A) Analysis of in vivo cytotoxic lysis on day 7 after primary immunization. (B) The percentage of specific lysis summarized as the means of the
three independent experiments. (C) Antibody levels in serum collected on day 14 after immunization and detected by ELISA. Data shown are
representative from three independent experiments. *, p,0.05. ns, p.0.05. Killed V stands for the killed H5N1 vaccine and vehicle stands 7.5%
ethanol in saline solution.
doi:10.1371/journal.pone.0034865.g001
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negative (Tc17) and only 0.4% were IFN-c-positive/IL-17-
negative (Tc1). In addition, there was an increased appearance
of splenocytes staining positive for both cytokines (1.4%). The
results suggested that PZQ facilitated Tc17 cell differentiation.
Tc17 cells were the main effectors for cytotoxic
responses
To examine whether the induced IL-17-positive were the major
effectors for the cytotoxic activity, we employed CD8, IFN-c or
IL-17 KO mice in the cytotoxicity assays. The cytotoxic response
was almost entirely eliminated in the CD8 KO mice (Fig. 3A) and
the enhancing effect of PZQ on the response was reduced in the
IFN-c and eliminated in the IL-17KO (Fig. 3B–C). The results
demonstrated that PZQ as adjuvant can enhance cytolytic
response via activation of IL-17-positive Tc17 cells.
PZQ enhanced protection against H5N1 lethal challenge
To determine whether vaccination by the killed viral vaccine
plus PZQ could protect animals against lethal H5N1 viral
challenge, mice were vaccinated with a low dose (0.1 mg) of killed
H5N1 vaccine with or without PZQ (0.5 mg PZQ/0.1 mg antigen)
and challenged on week four after the vaccination. The killed
vaccine alone or the killed vaccine with vehicle reduced the viral
load in the lungs. Significantly greater reduction of viral load was
observed in the mice immunized with the killed vaccine plus PZQ
(Fig. 4A). Furthermore, the survival rate of mice vaccinated by the
killed vaccine plus PZQ was 60% versus the 40% of those
vaccinated with the vaccine without PZQ (Fig. 4B). The results
Figure 2. Analysis of antigen-specific cytokine productions in CD8
+ T cells. Splenic cells were isolated from C57BL/6 mice on day 7 after
immunization and stimulated with NP peptide for 6 h in culture. (A) Intracellular staining for IFN-c, IL-17 and CD8
+ was analyzed by FACS. (B) The
percentages of positive-stained cells are summarized as the means from three independent experiments. (C) Co-staining for IFN-c and IL-17 in CD8
+ T
cells. (D) The percentages were shown as the means of three independent experiments. **, p,0.01. ns, p.0.05.
doi:10.1371/journal.pone.0034865.g002
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conferring greater protection.
We next tested if higher dose of killed influenza vaccine could
provide a greater protection. We used 1 mg of the killed vaccine
with or without the PZQ as adjuvant (0.5 mg PZQ/1 mg antigen).
In agreement with results above, a significantly greater cytotoxic
response and a higher percentage of Tc17 cells were induced by
1 mg of killed vaccine plus PZQ compared with the vaccine
without PZQ. The levels of antibody were again not different
between the groups (Fig. 5A–C). After lethal challenge, mice
vaccinated by the killed vaccine with or without PZQ were 100%
protected. However, mice vaccinated by the killed vaccine plus
PZQ showed delayed weight loss and the lowest viral loads in their
lungs compared with other groups (Fig. 5D–F). The data
supported a strong correlation between a high level of Tc17-
mediated cytolytic response and protection.
Tc17 cells are involved in protection against H5N1 virus
infection
To test the importance of a Tc17-mediated cytolytic response
during the H5N1 viral infection, primed CD8
+ T cells from
vaccinated mice were used for adoptive transfer of protection. The
cells were isolated on day 7 from IFN-c KO, IL-17KO or wild-
type C57BL/6 mice that had been vaccinated with 1 mg killed
H5N1 vaccine with or without PZQ (0.5 mg PZQ/1 mg antigen).
CD8
+ T cells were purified to 96–98% of purity and adoptively
transferred intravenously into naı ¨ve syngeneic mice at 5610
6 cells
per recipient mouse immediately before H5N1 viral challenge.
Naı ¨ve mice that did not receive cells developed high viral loads
and were all dead by day 12. Primed CD8
+ T cells from IFN-c
KO or wild-type mice could provide some degree of protection
with delayed deaths and lower viral loads. However, CD8
+ cells
from IL-17KO mice gave very little reduction in either death rate
or viral load (Fig. 6A–B), suggesting a protective role of Tc17
during the viral infection. These data suggest that both Tc1 and
Figure 3. In vivo cytotoxic responses in immunized wild-type, CD8KO, IFN-cKO and IL-17KO mice. Mice were tested at day 7 after
immunization and the percentage of specific lysis is summarized. (A) In vivo cytotoxic lysis was tested in the wild-type and CD8KO mice. (B) In vivo
cytotoxic lysis in IFN-c KO mice. (C) In vivo cytotoxic lysis in IL-17KO mice. The same data from wild-type mice is shown in each panel for reference.
*, p,0.05. **, p,0.01. ***, p,0.001. ns, p.0.05. KO stands for knockout.
doi:10.1371/journal.pone.0034865.g003
Figure 4. Protection against a highly pathogenic avian influenza virus H5N1 infection. Mice were challenged one month after vaccination
(0.5 mg PZQ/0.1 mg antigen). (A) Viral loads in the lungs on day 7 after virus infection. (B) Survival curves. Data are analyzed from three separate
experiments and each had 5 animals. *, p,0.05.
doi:10.1371/journal.pone.0034865.g004
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Tc17 apparently contributed more.
Such cell-mediated immune responses can be through recog-
nition of conserved epitopes of internal proteins of the influenza
virus such as NP and PA [23–25], consequently they may protect
animals from heterologous viral challenge. To test this, we
vaccinated mice with 1 mg killed H1N1 vaccine plus PZQ or
1 mg killed H5N1 vaccine plus PZQ (0.5 mg PZQ/1 mg antigen)
and challenged with H5N1 virus. Cross-protection did not occur
as shown in Figure S1A. In addition, the primed-CD8
+ T cells
induced by either vaccination were isolated on day 7 after
vaccination and transferred to normal syngeneic mice, which were
then challenged with H5N1 virus. The protective effect during
virus infection was then measured by the survival rate and the
virus titer in the lungs. Although the killed H5N1 vaccine plus
PZQ-primed CD8
+ T cells protected against H5N1 challenge, the
corresponding killed H1N1 vaccine plus PZQ-primed CD8
+ T
cells did not (Fig. S1B–C). The results suggested that the killed
vaccine with PZQ as adjuvant did not support cross-protection.
Discussion
Virus-specific cytotoxic T lymphocyte activity has been
demonstrated to be essential for controlling influenza viral
infections [7,8], yet the widely used formalin-inactivated vaccines
do not induce CTL responses specific for influenza virus antigens
[26]. In this study we found that a single immunization of mice
with the killed H5N1 viral vaccine plus PZQ was able to induce
IL-17-secreting CD8
+ T cells, many of which also secreted IFN-c.
Vaccination with the killed vaccine plus PZQ also gave
significantly greater protection to the mice against a lethal virus
challenge infection. There was reduction of virus loads in the lung
tissues and prolonged survival. This protection was associated with
the Tc17 cell activation since an adoptive transfer of these cells
Figure 5. Effect of adding PZQ to high-dose (1 mg) killed H5N1 vaccine. Mice were immunized with high-dose killed H5N1 vaccine (0.5 mg
PZQ/1 mg antigen). (A) In vivo cytotoxic lysis assay performed on day 7 after primary immunization. (B) The percentage of Tc cells at day 7. (C)
Antibody levels in sera collected on day 14 after immunization and assayed by ELISA. (D) Weight change of surviving mice and (E) viral loads in the
lungs. Mice were infected x days after immunization and viral load was measured 7 days later. (F) Survival curves. Data are analyzed from three
separate experiments and each had 5 animals. *, p,0.05. ns, p.0.05. 1 mg V stands for 1 mg killed H5N1 vaccine.
doi:10.1371/journal.pone.0034865.g005
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for the first time, that protective virus-specific Tc17 cells can be
primed in vivo during vaccination. How PZQ affects the T cell
responses in such a specific way remains to be elucidated.
Previous studies demonstrated that inactivated vaccines against
influenza viruses induced antibodies specific for the virus but not
effective CTL responses [26,27]. However, in the present study,
formalin-inactivated vaccines against H5N1 virus alone induced
CTL responses. This situation has been described in several
previous publications. Particularly, it was reported that formalin-
inactivated H5N1 whole virus particles were effective for induction
of both cytotoxic T-lymphocyte and antibody responses against
highly pathogenic avian influenza viruses in vivo [28]. This
induction of CTL presumably goes through the so-called cross-
presentation pathway. Although the pathway is present in APCs,
adjuvants may facilitate entry of antigens into it. Another report
showed that heat-aggregated influenza virus induced significant
CTL responses [29]. It is tempting to speculate that inactivated
vaccines might stimulate dendritic cells to indirectly activate CTL
precursors because ultraviolet-inactivated influenza virus induced
IFN-a production in plasmacytoid dendritic cells [30]. Further
investigation is needed to clarify this point.
Although Tc17 cells have been shown to promote inflammation
during the development of experimental autoimmune encephalo-
myelitis and influenza infection [22,31,32], their function was not
clear. Several reports have indicated that IL-17-producing cells
that were not cytotoxic [33–35], whereas others proved they had
cytotoxic phenotype [20,22,36]. In addition, in vivo transfer of in
vitro-derived Ag-specific Tc17 cells has been shown to clear lethal
doses of influenza [36,37]. Our present finding of an association
between increased Tc17 response and increased protection that
could be adoptively transferred indicates that Tc17 cells may be
critical for anti-viral activity.
It has been reported by others that although most Tc17 cells
produced IFN-c, a small part of the Tc17 cell population was IFN-
c negative in some individuals [20,22,38]. Acquiring the Tc1
phenotype (IFN-c production) was reported to be not critical for
the anti-viral activity of Tc17 cells [22] but the biological function
of IFN-c in Tc17 cells is not clear. In our study, PZQ induced both
populations of Tc17 cells, IFN-c negative cells and IFN-c positive
cells, during killed H5N1 vaccination. However, our studies in KO
mice indicated that when depleted of IFN-c the Tc17-mediated
cytotoxic and anti-viral responses were impaired, indicating that
acquiring the Tc1 phenotype may be necessary for the
development of Tc17-mediated cytotoxic and anti-viral activity.
Effector Tc1 cells, the classical cytotoxic T cells that produce
IFN-c and TNF-a, have been demonstrated to control lung
inflammation during acute influenza virus infection [39–41]. It
was striking that here NP366–374 peptide-specific Tc1 cells were
not expanded, and yet IFN-c positive Tc17 cells were expanded.
Till now, little work has been done to clarify whether IFN-c
inhibits or promotes the development of Tc17 and it is possible
that Tc1 cells could produce IL-17 to convert to Tc17 cells in the
presence of PZQ. Further studies are needed to clarify it.
There is considerable interest in the development of universal
vaccines that can afford protection against different subtypes of
influenza A virus [6,42]. In contrast to antibody responses, CTL
differentially recognize and respond to influenza virus of different
subtypes, mainly recognizing epitopes derived from conserved
proteins [43–45]. It has been shown that CTL specific for seasonal
influenza virus can cross-react with H5N1 virus [45,46], and the
cross-reactive CTL responses also afford heterosubtypic immunity
[47]. However, in the present study, we found that there was no
cross protection against H5N1 virus infection by CTL specific for
H1N1 viruses. We speculate that there are some mutations of
epitopes derived from internal proteins between the two variants of
influenza virus. Next, we will analyze the CTL responses to
different epitopes of internal viral proteins, comparing mice
immunized with either killed H5N1 or killed H1N1 vaccine plus
PZQ.
Both antibodies and CTL specific for H5N1viruses are critical
for protection against H5N1 virus infection. This is partly because
avian influenza virus strains replicate both in the upper respiratory
tract and in the lung and intestine [48,49]. Interestingly, the
Figure 6. Adoptive transfer of sensitized CD8
+ T cells delays the development of virus infection. Each mouse received 5610
6 cells and
was then challenged immediately with a lethal dose of H5N1 virus. (A) Viral loads in the lung of mice assayed on day 7 after infection. (B) Survival
curves. Data are analyzed from three separate experiments and each had 5 animals. *, p,0.05. **, p,0.01. WT CD8 T cells stands for CD8
+ T cells from
wild type mice immunized with killed vaccine plus PZQ. IFN-c KO CD8 T cells stand for CD8
+ T cells from similarly immunized IFN-c KO mice. IL-17KO
CD8 T cells stands for CD8
+ T cells from similarly immunized IL-17KO mice.
doi:10.1371/journal.pone.0034865.g006
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were obtained by immunizing with either 0.1 mgo r1mg H5N1
inactive vaccine. It appears that PZQ preferentially promoted cell-
mediated immunity, not antibody responses, and we need further
experiment to understand the mechanism.
In summary, we show for the first time that the addition of PZQ
as an adjuvant to killed H5N1 vaccine induces strong Tc17-
mediated CTL and enhances protection against a highly
pathogenic avian influenza virus infection. PZQ may therefore
represent a promising chemical adjuvant for killed vaccines and
provide a novel strategy where the induction of a broad CD8
+ T
cell immunity is required.
Materials and Methods
Reagents and Animals
Praziquantel (NCPC, Hebei, China) was first dissolved in
ethanol to 6.7% and subsequently diluted to 0.5% with the saline
solution. The vaccine delivery vehicle was therefore 7.5% ethanol
in saline solution. Fluorescently labeled anti-mouse monoclonal
antibodies for flow cytometry were purchased from BD Pharmin-
gen (San Diego, CA, USA). Influenza virus nucleoprotein (NP)
NP366–374 peptide representing the CD8
+ T-cell epitope
(ASNENMETM) was synthesized by GL Biochem Co., Ltd.
Adult female C57BL/6 mice at 8–10 weeks of age were purchased
from Animal Institute of Chinese Medical Academy (Beijing,
China). IFN-cKO (B6.129S7-Ifng
tm1Ts/J) mice were purchased
from the Jackson Laboratory (Bar Harbor, Maine). CD8 KO mice
(C57BL/6 background) and IL-17 KO mice (C57BL/6 back-
ground) were from kindly provided by Richard Flavell (Yale
University School of Medicine, New Haven, CT). All animal
protocols (#28482-rev1) were approved by the Animal Welfare
Committee of China Agricultural University and housed with
pathogen-free food and water under 12 h light-cycle conditions.
Vaccines
Highly pathogenic avian influenza virus, (HPAIV, H5N1, A/
Chicken/Henan/1/04) was maintained at BSL-3 facility (China
Agriculture University, Beijing, China). Whole H5N1 chemically
inactivated viruses was used as killed vaccine and was provided by
Dahuanong Animal Health Inc. (Guangdong, China). The
inactivated vaccine was prepared by treating the H5N1 virus
(A/Chicken/Henan/1/04) with 0.2% formalin at 37uC for 24 h.
The vaccine was tested for its immunogenicity in mice and
inability to infect chicken embryos. H1N1 killed vaccine was
kindly supplied by Zhejiang Tianyuan Bio-Pharmaceutical Co.,
Ltd. (Zhejiang, China). The protein content of the vaccines was
determined with Pierce BCA Protein Assay Kit (Rockford, IL,
USA).
Immunization
The C57BL/6 mice were randomly divided into five groups
(n=10 each). The killed vaccines, at a dosage of 0.1 mgo r1mg
and with/without adjuvant (0.5 mg PZQ/0.1 mgo r1mg antigen),
injected intramuscularly. The volume of each dose was 100 ml.
Virus challenge
Four weeks after the single dose of immunization, mice were
challenged with a lethal dose (10 LD50) of mouse-adapted strain
A/Chicken/Henan/1/04 (H5N1) by intranasal administration of
20 ml of the viral suspension. This infection caused death of all the
unimmunized mice within 7–12 days.
In vivo CTL assay
In vivo cytotoxic assay was performed using splenocytes from
naı ¨ve C57BL/6 mice pulsed with 10
26 M NP peptide and labeled
with a high concentration of CFSE (15 mM, CFSE
high cells) as
target cells. A portion of the same splenocytes was labeled with a
low concentration of CFSE (0.5 mM, CFSE
low cells) without
peptide pulse as a non-target control. The target and control cells
were mixed in a 1:1 ratio and injected into immunized mice at
2610
7 total cells per mouse via the tail vein on day 7 after primary
immunization. Four hours later lymph nodes and the spleens of
injected mice were removed and the target and control cells were
analyzed by their differential CFSE fluorescent intensities using a
FACSCalibur (BD Biosciences, USA). Specific lysis was calculated
using the following formula: ratio=percentage CFSE
low/percent-
age CFSE
high. Percentage specific lysis=[12(ratio unprimed/ratio
primed)] 6100.
Detection of anti-H5N1 antibody
Serum anti-H5N1 antibody was measured with an enzyme-
linked immunosorbent assay (ELISA). On day 14 after immuni-
zation, serum was collected. ELISA was performed in a 96-well
polystyrene microtiter plate with reagents consisting of inactivated
H5N1 virus vaccine. Following the blockage with 3% of BSA for
1 h, the plate was incubated with diluted mouse sera in each well.
A second goat anti-mouse IgG Ab (Sigma,St. Louis, Mo) diluted
1,000 times was added. Ten milligrams of TMB tablet (Sigma,St.
Louis, Mo) was dissolved by 0.025 M phosphate-citrate buffer and
subsequently added to each well for color development. After the
reaction was stopped by 2 M H2SO4, the plate was read with a
plate reader at 450 nm/620 nm. The antibody titers were
determined by the absolute ratio of OD values of post/naive sera
at a cutoff ratio of 2.1.
Flow cytometric analysis
Splenic cells were isolated on day 7 after the final immunization
and stimulated with 10 mg/ml NP peptide in the presence of
brefeldin A (5 mg/ml) for 6 h at 37uC and 5% CO2. Collected cells
were fixed with 4% paraformaldehyde and permeabilized with
0.1% saponin (Sigma-Aldrich). For immunostaining of cytoplas-
mic IL-17 and IFN-c and surface CD8, the appropriate
concentrations of fluorescently labeled anti-mouse monoclonal
antibodies were added to permeabilized cells for 30 min on ice
followed by washing twice with cold PBS. Samples were analyzed
by a FACSCalibur.
Viral RNA determination
Total RNA was prepared from 10 mg lung homogenized and
extracted in Trizol (Invitrogen) according to the manufacture’s
instruction. DNase I treated RNA (2 mg) was used to reverse
transcribe into cDNA using a set of universal primers for influenza
A virus [50] as following: forward primer, 59-CGCAGTATTCA-
GAAGAAGCAAGAC-39; reverse primer, 59-TCCATAAGGA-
TAGACCAGCTACCA-39. Real-time PCR was performed to
amplify the hemagglutinin (HA) gene of H5N1 influenza virus
using SYBRH PrimeScriptH RT-PCR Kit (TaKaRa Inc, Japan).
The reaction was run on an ABI 7500 and data analysis was
performed using 7500 software v2.0 (ABI). The copy number of
the HA gene was calculated by using a HA-containing plasmid of
known concentration as a standard.
Adoptive transfer of CD8
+ T cells
On day 7 after primary immuzation with 1 mg killed vaccine
and PZQ, single-splenocyte suspensions were prepared from
PZQ Enhances Protection against H5N1
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+ T cells
were isolated and purified using the MagCellect Mouse CD8
+ T
Cell Isolation Kit according to the manufacturer’s protocol (R&D
Systems, Inc., Minneapolis, USA). Purity of each cell preparation
was 90–95%. The cells were adoptively transferred intravenously
into normal C57BL/6 mice at 5610
6 per recipient mouse.
Statistical Analysis
Results are presented as means 6 S.E.M. Student’s t test
analysis was used for data analysis. A value of p,0.05 was
considered to be statistically significant.
Supporting Information
Figure S1 Weak cross protection against H5N1 virus by
CTL specific for H1N1 virus. C57BL/6 mice were immu-
nized with 1 mg killed H5N1 vaccine plus PZQ or 1 mg killed
H1N1 vaccine plus PZQ (0.5 mg PZQ/1 mg antigen), and
challenged with H5N1 virus one month later. (A) Survival curves.
Alternatively, 7 days after immunization, CD8
+ splenocytes were
obtained and transferred to naive recipients that were immediately
challenged with H5N1 virus. (B) Viral loads in the lung on day 7
after infection. (C) Survival curves. Data are analyzed from three
separate experiments and each had 5 animals. CD8 T cells
(H5N1/PZQ) stands for CD8
+ T cells from C57BL/6 mice
immunized with 1 mg killed H5N1 vaccine plus PZQ. CD8 T cells
(H1N1/PZQ) stands for CD8
+ T cells from C57BL/6 mice
immunized with 1 mg killed H1N1 vaccine plus PZQ. *, p,0.05.
ns, p.0.05.
(TIF)
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